ArticleEndocrine2022
Age-related risk for second breast cancer and gynecological malignant neoplasms after differentiated thyroid cancer.
Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we aimed to investigate the age-related risk of second breast cancer (SBC) and second gynecological malignant neoplasms (SGMNs) in female differentiated thyroid cancer (DTC) survivors by utilizing the Surveillance, Epidemiology, and End Results (SEER) database.
methodsA total number of 55,622 female DTC patients were identified between 1975 and 2016, including 2168 patients who developed SBC and SGMNs. The Fine and Gray model was used to calculate the cumulative incidence and sub-distribution hazards ratios (SHR). Poisson regression analysis was employed to calculate the relative risk (RR) and standardized incidence ratio (SIR). Kaplan-Meier survival and log-rank test analyses were also performed.
resultsThe overall 40-year cumulative incidence of SBC and SGMNs was 18.9%. Their incidence in the adolescent and young adults (AYA) group increased slowly in the first 30 years, but then was rapidly elevated in the last decade. It increased gradually in the middle-aged adults group and in the first 25 years in the older adults group, but it scarcely increased thereafter. Both the middle-aged adults (adjusted SHR, 2.09; RR, 1.76) and the older adults (adjusted SHR, 1.32; RR, 1.58) groups had higher risks of developing combined SBC and SGMNs than the AYA group. The risks increased mainly in the early latency period. The three groups also had higher SIRs than the US general population. Besides, the best survival after SBC and SGMNs was observed in the AYA group.
conclusionsAge was an independent risk factor for SBC and SGMNs incidences among female DTC survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.